Using AI to Reduce Rework in Biotech Regulatory Submissions

Emerging biotech companies face intense pressure to get their drug candidates into trials and on the market quickly. Yet, regulatory submissions (like INDs or NDAs) often bounce back due to avoidable technical issues or missing elements, forcing rework cycles that eat up precious time. These delays can stretch for weeks or even months, as the FDA’s “Refuse to File” or technical rejection letters reset the clock on review ^[1]. The result is lost time-to-market and increased costs – setbacks that resource-strapped biotechs can scarcely afford. Fortunately, advances in AI-powered “pre-flight” checks promise to catch and fix these errors before the submission goes out the door. By automatically validating PDF compliance, catching broken links, and even suggesting improvements via generative AI, emerging biotechs can dramatically reduce the ping-pong of submissions and Health-Authority queries. This article explores how an AI-driven pre-flight module can help teams identify configured technical issues before submission and reduce avoidable rework. With the FDA now rolling out its own AI tools for regulatory review (including its agency-wide assistant ELSA, launched in June 2025) and the AI in regulatory affairs market projected to reach $3.9 billion by 2029, the urgency for sponsors to adopt AI-powered submission tools has never been greater. We'll also sidebar on a hot topic for document AI: Google's Gemini vs OpenAI's models for extracting structure from unstructured forms, and what each means for regulatory use cases.

In regulatory affairs, time is critical. A technical mistake in an eCTD (electronic Common Technical Document) submission can generate an FDA validation finding. FDA assigns each finding a severity and explains its potential effect on official receipt; a High error prevents processing and requires resubmission, while a Medium error may affect reviewability and may still be considered received. This technical-validation process is distinct from FDA’s filing review of an NDA, which can result in a refuse-to-file action when the NDA is incomplete. For emerging biotechs operating on limited runways, a months-long slip in timelines can mean postponed trials, missed funding milestones, or losing the competitive edge. Common culprits behind these rejections are often mundane – a PDF file that isn’t text-searchable, a broken hyperlink, a missing dataset – but their impact is severe. FDA’s eCTD validation criteria explicitly flag such issues (e.g. non-searchable scans, broken bookmarks or hyperlinks) as errors that must be corrected ^{[2] [3]}. FDA’s validation criteria specify the potential effect and corrective action for each error; sponsors should assess the applicable validation report and submission requirements rather than assume that every technical finding requires resubmission. This back-and-forth not only wastes time but also consumes regulatory team resources in scrambling to diagnose and remedy issues under duress. With the FDA now accepting eCTD v4.0 alongside v3.2.2 – and Japan's PMDA planning to make v4.0 mandatory by 2026 – the validation landscape is more complex than ever. The FDA updated its Specification for eCTD Validation Criteria as recently as October 2025, adding new error codes and tightening requirements. Clearly, prevention is better than cure: if these errors can be identified (and fixed) before submission, biotechs can avoid the rework cycle altogether and keep development timelines on track.

“Pre-flight checks” in the context of regulatory submissions refer to the comprehensive validation and quality assurance steps performed just before sending the dossier to a Health Authority. The term borrows from aviation, where pilots run pre-flight checklists to ensure everything is in order to avoid failure mid-air. Similarly, regulatory pre-flight checks aim to catch any technical or format issues that could derail the submission upon receipt. Traditionally, this might involve using eCTD validation software and manual QC checklists: ensuring all required files are present, verifying that PDFs meet agency specs, checking that hyperlinks and bookmarks work, confirming metadata (like sequence and application numbers) are correct, etc. For example, an eCTD publisher might manually click through every hyperlink in every PDF to confirm none are broken – a tedious but necessary process. Pre-flight also includes verifying the submission structure (module/section completeness) and ensuring no compliance “red flags” remain. Emerging biotechs often rely on consultants or publishing vendors for this, but manual checks are time-consuming and not foolproof. This is where AI-powered pre-flight modules come in. By automating and enhancing these checks with intelligent algorithms, an AI-based system can perform a thorough “dress rehearsal” of the submission in minutes, flagging any issues that would compromise acceptability. Think of it as an automated co-pilot: scanning configured documents and links against defined rules so the team can investigate findings before submission. It supports, but does not replace, formal validation and qualified human review.

It’s worth reviewing the typical pitfalls that trip up submissions – the very targets that our AI pre-flight system is designed to catch. Many of these are simple technical compliance issues that nonetheless have outsized consequences if overlooked:

• Broken or Incorrect Hyperlinks/Bookmarks: Regulators expect that navigation aids in PDFs (hyperlinks in text and bookmarks in the PDF sidebar) are fully functional and accurate. Broken links or missing bookmarks not only frustrate reviewers but are seen as quality issues. In fact, FDA’s validation rules include errors for “Broken bookmark” and “Broken hyperlink,” meaning a PDF with a link pointing nowhere will raise a flag ^{[2] [3]}. Even if not an outright rejection in all cases, incorrect links degrade the perceived quality of the submission and waste reviewer time ^[4]. Every hyperlink in an eCTD is supposed to use a relative path and point to the correct target; any mis-linked or non-working reference is a compliance mistake.

• PDF Formatting and Compliance Issues: Health authorities have detailed specifications for PDF documents. All PDFs usually must be text-searchable (not just scanned images), must have all fonts embedded, be in an acceptable version (e.g. PDF 1.4-1.7), and contain no active elements or security settings (no passwords, no audio/video, etc.) ^{[5] [6]}. PDFs should also open at 100% zoom and be optimized for fast web view according to FDA guidance ^[7]. Submitting a PDF that violates these rules can lead to technical queries. For instance, a document that is just a scanned image with no selectable text is explicitly flagged in FDA’s criteria (“document contains no text”) ^[8]. Likewise, a PDF with password protection or that isn’t set for “Fast Web Access” will trigger validation warnings ^{[9] [7]}. These seem trivial, but in aggregate they can cause a delay or a demand for resubmission.

• Missing or Non-Compliant Table of Contents: Regulatory submissions require a proper table of contents (ToC) to help navigate the many documents. A PDF without bookmarks/table of contents is a common mistake that impairs review. In fact, industry guidance emphasizes that ToCs are compulsory for reviewer efficiency ^[10]. If sponsors forget to include bookmarks in a long PDF, it reflects poorly – one might get asked to reformat and re-submit that file. Hyperlinked ToCs at the dossier level (eCTD backbone) and within each PDF (bookmarks) are both expected for a smooth review experience.

• Metadata and Structural Errors: These are less “glamorous” but equally critical checks. Examples include ensuring the correct regional XML backbone is present and all files are referenced in it, that the application number and sequence number in the metadata are correct (e.g. 6-digit app ID, 4-digit sequence) ^{[11] [12]}, and that no files are missing from the sequence. A file present in the folder but not referenced in the XML manifest is effectively invisible to the reviewer and thus a compliance error ^[13]. Similarly, using an incorrect Document Type Definition (DTD) or modifying the standard stylesheets can impair the submission – the FDA expects the three standard DTDs and a standard CSS in the util folder ^[14]. If a biotech isn’t careful, a tiny mistake like an extra space in the sequence number or a stray unreferenced file can result in an authority asking for correction.

• Study Data and Format Issues: (Beyond document PDFs) if the submission includes study data (like SDTM/ADaM datasets), there are additional technical criteria. For instance, FDA has Technical Rejection Criteria (TRC) for study data that will auto-reject an application missing required data formats. While our focus here is on documents, a comprehensive pre-flight would also verify that required datasets (and define.xml files) are present and conform to standards, to avoid immediate rejection of a clinical or nonclinical section.

For a lean biotech team, keeping track of all these details is challenging – especially now that FDA supports both eCTD v3.2.2 and v4.0 simultaneously, each with its own validation criteria and XML schemas ^[15]. It's easy to see how one or two can slip through in the final hours of assembly. And as noted, the cost of even minor compliance slip-ups is high. This is precisely why an AI-driven solution is so valuable: it can relentlessly check every detail without fatigue, using rules and learning gleaned from thousands of past submissions.

One core feature of AI pre-flight systems is automated PDF compliance checking. Instead of relying on human eyes or basic scripts, the AI can intelligently scan each document against a library of regulatory rules and best practices. This goes beyond just running the PDF through a validator – an AI can interpret the document’s properties and content to catch subtler issues and even fix them. Key capabilities include:

• Format and Accessibility Scans: The AI checks that every PDF is text-selectable and not just an image. If a document is detected as image-only (no extractable text layer), it flags it as non-compliant (mirroring FDA’s rule that submissions be text-searchable ^[8]). It might even apply OCR to provide a quick fix, making the document searchable without altering content. The system also verifies that fonts are embedded and no PDF/A compliance issues are present (missing fonts can cause rendering problems on the reviewer’s end). Similarly, it can confirm there are no prohibited elements (no multimedia, no JavaScript, no 3D graphs, etc., unless explicitly allowed).

• Bookmark & ToC Validation: Here the AI ensures that bookmarks exist where expected (e.g. every document over a certain length should have a bookmarked table of contents) and that those bookmarks are correctly linked. It can programmatically traverse each bookmark to confirm it goes to the intended page. If any bookmark leads to a missing page or a wrong destination, that’s essentially a “broken bookmark” error as defined by regulators ^[2]. The AI would flag, “Document X has a bookmark pointing to page 15 which does not exist,” allowing the publisher to correct the bookmark before submission. If a PDF lacks a ToC entirely, the AI could suggest inserting one (some advanced tools even auto-generate a bookmark hierarchy from document headings – a feature eCTD assembly software have offered ^[16]).

• Hyperlink Testing (Internal and External): All hyperlinks within the submission are automatically tested in silico. The AI can extract every link (for example, hyperlinks from the summary documents that point to appendices or literature references) and verify the target exists in the submission package. If a link’s target file is missing or misnamed, the AI marks it as a broken link (which would otherwise trigger a validation error ^[3]). In addition, it checks that external links (e.g. a reference to an external website or a file path) are not present in regulatory documents, since agencies discourage or forbid hyperlinks that go outside the submission ^[17]. Any external URL or non-relative path would be listed so the sponsor can remove or replace it (for instance, by providing the referenced content in Module 4 or 5 instead of linking out). Essentially, the AI does a thorough link crawl of the entire eCTD, something that would be tedious manually.

• Standards and Metadata Checks: The AI can verify PDF version and settings. For example, FDA recommends enabling “Fast Web View” on PDFs for quicker loading ^[7] – an AI tool can open the PDF properties to ensure this is enabled and even toggle it on if not. It also checks each PDF’s opening settings (like default zoom, navigation tab) to ensure they’re set per guidelines (open at 100% with bookmarks panel, etc.) ^[18]. These are fine details, but collectively they contribute to a polished submission. Through machine rules, the AI ensures no PDF security is applied (e.g. printing or copying not disabled, no passwords) ^[5]. It can also calculate and verify checksums for each file and cross-check with the XML backbone, catching any mismatch in file integrity before the agency does.

• Automated Correction & Formatting: Beyond just identifying issues, an advanced system may offer one-click fixes for some problems. For instance, if an eCTD’s XML backbone is missing a reference to a file, the tool might prompt to automatically insert the correct XML entry. If a PDF is above the recommended file size or not optimized, the tool could invoke a compression routine. If fonts aren’t embedded, it could attempt to embed them. This moves from pure “validation” to active repair, reducing the manual work on the regulatory publisher.

By performing configured checks across the dossier, AI-driven pre-flight can help teams identify obvious technical issues before submission. Results should be reviewed, corrected where appropriate, and confirmed through the organization’s formal validation process; automated checks do not guarantee FDA receipt, reviewability, scientific adequacy, or approval. As a bonus, using such tools repeatedly also educates teams on common errors to avoid, gradually improving overall document quality culture.

A standout feature of the pre-flight module (and a common source of headaches) is broken-link detection. Hyperlinks are the threads that tie a submission’s narrative together – for example, a Clinical Overview might hyperlink to detailed results in a Clinical Study Report, or a Quality summary might link to specific sections of a validation report. If those threads break, the reviewer is left frustrated and the sponsor embarrassed. Even though a broken link might seem minor, regulators take them seriously as a sign of quality control issues. All hyperlinks and bookmarks must be checked and correct prior to submission ^[4].

Manual link checking is painstaking: one has to click every link in every PDF and ensure it opens the intended document or section. AI completely transforms this task. The pre-flight AI automatically harvests every hyperlink and cross-reference in the submission and programmatically verifies each one. This includes:

• Internal document links: The AI identifies links within a PDF (e.g. a hyperlink from text to another section of the same PDF via a named destination or page number) and tests that the destination exists. It catches cases where a hyperlink points to a page that has since moved or a bookmark that was renamed – scenarios that would result in a dead link if clicked. For instance, if a hyperlink in Module 2.5 points to Appendix 3 in a PDF but the appendix numbering changed, the AI will catch that mismatch.

• Cross-document links: These are links pointing from one document to another (common in eCTD, where you might link from a summary document to a study report in Module 5). The AI can simulate the eCTD viewer by resolving the relative link target (e.g. ../../m5/53-study-report.pdf#page=45). If the target file 53-study-report.pdf is missing or the specified page doesn’t exist, that’s flagged as a broken hyperlink error. According to FDA’s eCTD criteria, a “hyperlink pointing to a file that does not exist” is exactly the definition of a broken link ^[3], which would be a technical issue to fix. The pre-flight report will list all such bad links so they can be corrected (e.g. update the link to the correct file or ensure the file is included).

• External and invalid links: If any link points to an external web URL or an absolute file path (which should not happen in a self-contained submission), the AI will flag those too as invalid. For example, a hyperlink to http://clinicaltrials.gov/... in a submission is not advised; the AI would recommend removing it or providing the referenced information in an attachment instead ^[17]. Similarly, any link that uses a non-relative path (say C:\Documents\...) is clearly a packaging error – the AI catches these non-relative hyperlink cases which are explicitly disallowed ^[19].

• Bookmark link verification: Bookmarks in PDFs are essentially just navigational links (within the PDF or even to other PDFs). The AI checks that each bookmark actually lands on a valid page in the document or target. It detects “corrupt” or “inactive” bookmarks – e.g. ones that don’t jump anywhere ^{[20] [21]}. These could happen if a section was removed but the bookmark left in place, etc. Such orphaned bookmarks again undermine the professionalism of the dossier, so catching them is important.

By catching navigation issues upfront, the AI spares the biotech from a scenario where the regulator finds them instead. Consider the reviewer experience: clicking a link in a summary and getting an error or blank is not only a nuisance but slows down review as they must manually hunt for the referenced content. Enough broken links and a reviewer could ask for a corrected submission copy. FDA’s eCTD validation criteria classify a broken hyperlink as a Medium error: it may affect reviewability, and the submission might still be considered received. Teams should correct the finding when required rather than infer that a broken link will result in a substantive filing decision. An industry guide noted that incorrect links “degrade the perception of quality” and explicitly waste reviewers’ time ^[4]. Conversely, a submission with flawless cross-references creates an impression of thoroughness and is easier to review, potentially speeding up the assessment.

Our AI pre-flight module makes broken-link detection essentially a non-issue for the sponsor. In testing, it scans hundreds of links within seconds and produces a report like: “5 broken links found in Module 2.5.1: link on page 12 points to missing file X; link on page 47 has an incorrect page target…” etc. The regulatory team can then quickly fix those before sending the dossier. It illustrates how automated checks can speed review of a repetitive, important task, subject to validation of the tool’s results. By ensuring every hyperlink and bookmark works as intended, the AI helps deliver a submission that “just works” for the reviewer – no frustrating dead ends. And that directly contributes to avoiding rework: if the initial submission has no navigation issues, there’s no need for a second cycle to fix them.

While catching technical errors is critical, AI in regulatory is now moving rapidly into the realm of content quality and completeness. What was once a future aspiration is becoming today's reality: AI that not only checks for broken links, but also reads the content of your submission and offers suggestions to strengthen it. This is where generative AI (GenAI) comes into play, moving beyond fixed rules to more intelligent guidance. A 2025 McKinsey analysis found that gen-AI-assisted medical writing can reduce the end-to-end cycling time for clinical study reports by 40%, and that AI-powered platforms have cut first-draft CSR writing time from 180 hours to 80 hours while reducing errors by 50%. Our demo's pre-flight module is evolving to incorporate GenAI-driven suggestions that could preempt questions from regulators and improve the submission's chances of acceptance on the first pass.

What might these GenAI suggestions look like? A few examples illustrate the possibilities:

• Pre-empting Agency Queries: One of the most promising use cases is using AI to predict what questions a health authority reviewer might raise – and prompting the sponsor to address them proactively. By analyzing prior correspondence and common deficiencies, a GenAI system could flag, for instance, “In similar INDs, FDA often asks for justification of the starting dose – consider adding a rationale in section X.” Essentially, the AI uses the company’s and industry’s historical data (meeting minutes, review queries, rejection rationales) to anticipate and satisfy agency queries in advance ^{[22] [23]}. As one regulatory expert noted, “the obvious next step… will be for Regulatory AI tools to proactively suggest improvements to submissions while they are still a work in progress, based on automated lookups of previous Agency correspondence and the latest regulatory intelligence.” ^[23]. This means your pre-flight AI might say: “Health Canada recently updated guidance on elemental impurities – ensure your Module 3 includes that assessment”, or “FDA asked you a similar question in last year’s submission; consider addressing it now.” The benefit is huge: heading off deficiencies can save an entire review cycle or avoid a clinical hold.

• Content Consistency and Completeness: GenAI can analyze the narrative across documents to spot inconsistencies or missing pieces. For example, if the Phase 2 clinical study results mentioned in Module 2 are not actually included or elaborated in Module 5, the AI can warn about the gap. Or if the dosing regimen stated in the Clinical Overview differs from what’s in the protocol, it can highlight that discrepancy. These are the kinds of content issues that human reviewers catch, leading to questions. AI can serve as an intelligent second pair of eyes on the dossier’s scientific content, ensuring internal consistency. It might also check for completeness against known frameworks: e.g., in a quality section, if no data on batch analysis is found, it might suggest that data should be added per ICH guidelines.

• Clarity and Readability Suggestions: Taking a cue from large language models’ strength in text generation, a GenAI could even suggest rewordings or additions to improve clarity. For instance, it might flag a particularly convoluted sentence in a clinical summary and suggest a clearer phrasing (while of course leaving final judgment to the human authors). It could identify sections where an explicit conclusion or risk assessment is expected but not provided, nudging the writer to include one. Essentially it’s like a super-smart editor tuned to regulatory expectations.

• Guidance Compliance Checks: Generative models can be fed the relevant guidances (FDA/EMA guidelines, ICH, etc.) and then compare the submission content to those expectations. The AI might then generate a prompt like: "ICH M4Q says a justification for starting materials should be included, but I did not find it in your Module 3.2.S – you may want to add that to avoid questions." This extends the pre-flight from pure technical validation into the domain of regulatory intelligence – ensuring the content aligns with the latest requirements. As noted in an analysis by industry experts, keeping up with myriad global requirement updates is itself a challenge, one that AI can help with by monitoring changes and reminding teams to comply ^{[24] [25]}. Notably, the FDA itself is now using AI on the review side: its ELSA (Electronic Language System Assistant) tool, launched in June 2025, helps FDA reviewers analyze submissions, compare labels, and summarize adverse event reports. In December 2025, the agency expanded to agentic AI capabilities for all employees. This means the bar for submission quality is rising – AI-savvy reviewers may spot inconsistencies and gaps even faster than before, making sponsor-side AI pre-flight tools not just helpful but essential.

• Suggested Fixes for Technical Issues: Going beyond identifying issues, a GenAI system could also propose solutions. For example, if a hyperlink is broken, the AI might attempt to guess the intended target (maybe based on similar text elsewhere or file names) and suggest, “Link on page 5 likely meant to point to Appendix B – shall I relink it to the correct file?” For missing bookmarks, it could automatically create a draft table of contents for the user’s review. These generative fixes would streamline the remediation process significantly.

All of these capabilities transform the pre-flight check from a reactive error-hunting exercise into a proactive enhancement process. Instead of just telling you what's wrong, the AI starts to tell you how to make it better – how to strengthen the submission for a smoother approval. This is no longer a future aspiration – it's happening now. According to McKinsey's 2025 regulatory affairs benchmark, roughly 80% of top pharma companies are modernizing their regulatory information management systems (RIMS), and many are expanding AI beyond basic writing tools into structured content and collaborative authoring ^[26]. Early applications of such AI guidance have shown impressive efficiency gains: for example, pilots where AI distilled past review letters and helped craft better initial submissions saw up to 80% faster processing and far fewer handoffs ^{[27] [23]}. McKinsey estimates that these six AI-driven building blocks could unlock as much as $180 million in net present value for priority assets by slashing filing timelines from months to weeks. The human team still makes the decisions and final edits (ensuring scientific validity and compliance), but the AI can do a lot of heavy lifting in analyzing data and past knowledge to provide actionable insights.

To put it simply, GenAI-driven pre-flight modules now function like an expert colleague – one who has read every guidance and seen thousands of submissions, and can whisper in your ear: "You might want to add X, double-check Y, and clarify Z, because that's what the regulators will be looking for." For emerging biotechs that may not have a deep bench of ex-regulator experts, this is an equalizer. It means even small teams can benefit from a vast collective intelligence baked into their tools. Our demo's roadmap includes these GenAI suggestions as a centerpiece, because we believe the ultimate goal is not just zero technical errors, but also fewer content-related questions and a faster path to acceptance.

(Sidebar: We acknowledge that with GenAI suggestions, human oversight remains vital. The AI might propose something incorrect or irrelevant on occasion – hence a responsible implementation always involves a human in the loop to review AI-proposed changes. The vision is an AI-assisted workflow where humans and AI collaborate, rather than full automation in critical decision-making.)

To illustrate how all these pieces come together, let’s walk through our AI-powered pre-flight module – the hero feature of the platform demo for regulatory submissions. The goal of this module is to provide an additional quality-control step that helps teams identify configured technical findings before submission. Here’s an inside look at its workflow and capabilities, showcasing why it’s a game-changer for emerging biotechs:

1. Submission Ingestion: The process starts when you upload or assemble your draft eCTD sequence into the platform. The AI module ingests the entire set of files – all PDFs, the XML backbone, and any supporting data files. Thanks to cloud computing, it can handle large volumes (hundreds of documents, thousands of pages) swiftly. In our demo, a ~10,000-page submission (multiple studies, modules 1-5) can be ingested in just a couple of minutes for full analysis.

2. Automated Validation Suite: Once ingested, the module runs an automated validation suite covering all the compliance checkpoints discussed earlier. This includes: scanning each PDF for text-searchability and annotations, verifying bookmarks and hyperlinks, checking file integrity and XML references, ensuring naming conventions and metadata are correct, etc. The AI doesn’t rely on a single approach; it combines rule-based checks (e.g. “are sequence numbers 4 digits?”) with machine learning where appropriate (e.g. computer vision to detect if a page is a scanned image or has weird formatting). Essentially, it’s performing a multi-point inspection of the submission, akin to how a seasoned regulatory operations expert would – but faster and more comprehensively.

3. Issue Identification and Categorization: Any findings are logged and categorized by severity. For example, missing Module 1 documents or a corrupt study data file might be marked as Critical (must fix before submission), whereas a minor PDF bookmark zoom setting might be Low severity (doesn’t halt submission, but nice to fix for professionalism). The output is an actionable checklist. A snippet from a sample report might say:

• Critical: Document m2_5_clinical_overview.pdf is not text-searchable (scanned image) ^[8]. Fix: Convert to searchable PDF via OCR.

• High: 3 broken hyperlinks in m2_5_clinical_overview.pdf (link targets not found) ^[3]. Fix: Update or remove invalid links (specifics given).

• High: Module 4 study report file study123.pdf is present in folder but not referenced in the XML backbone ^[13]. Fix: Add reference to XML or remove file.

• Medium: 5 bookmarks in study123.pdf are pointing to non-existent pages ^[2]. Fix: Update bookmarks (list provided).

• Medium: Document tox_summary.pdf uses non-embedded font (Helvetica) ^[28]. Fix: Embed fonts and regenerate PDF.

• Low: Document module2-intro.pdf does not open in “Fit Width” view (not using Inherit Zoom) – not required but recommended ^[29]. Fix: Set Inherit Zoom for consistency.

Each item includes a brief explanation and a recommended fix, as shown. This level of detail saves the team from having to diagnose the problem; the AI does that for you.

4. One-Click Fixes and Auto-Corrections: For many issues, the module offers an auto-fix option. In the demo, a user can select an issue like the non-searchable PDF and click “Auto-correct.” The system will perform OCR on that PDF, replace the file with a text-layered version, and update the submission package – all logged for audit trail. Similarly, for missing XML references, it can open the backbone, insert the needed entry for the file, and validate the XML. The user always has control (you can choose to accept the AI’s fix or do it manually), but these quick fixes can resolve issues in seconds that might take hours manually. Our pre-flight module essentially combines a validator with a repair tool.

5. GenAI-Powered Recommendations: After technical issues, the module generates a section of “AI Recommendations”. This is where the earlier discussed GenAI suggestions appear. In the demo scenario, the AI might output notes like: “Recommendation: Add a brief conclusion to Module 2.7 to summarize the overall clinical findings. Currently, the summary ends without a conclusion, which regulators often expect.” Or “Note: The CMC section does not mention a stability commitment. Consider stating your plan, as this is commonly requested by authorities.” These are not hard requirements, but they are drawn from the AI’s training on prior submissions and guidelines, acting as value-added advice. Users can review these suggestions and decide whether to implement them. Even if they choose not to, it prompts a thoughtful check: Did we intentionally omit that? Are we comfortable with it? It’s like having a junior reviewer pre-check your work, which is incredibly useful for small teams.

6. Interactive Issue Dashboard: The results are presented in an interactive dashboard UI. Each issue can be clicked to reveal more details, e.g., clicking a broken link issue could show the exact text of the link, the source page, and the missing target. The interface can highlight the location in the PDF – for instance, opening the PDF to the page with the broken link for quick context. This greatly speeds up the correction process. Instead of combing through a 200-page document to find where a link is, the AI pinpoints it. The dashboard also updates dynamically if issues are fixed – so teams can re-run the check after fixes and see a clean bill of health.

7. Team Collaboration and Tracking: Since multiple people might be working on a submission, the pre-flight module integrates with collaboration features. Issues can be assigned to an owner (e.g. assign the CMC writer to fix a Module 3 issue, the publishing specialist to handle a PDF formatting fix). The system can track when an issue is resolved and by whom. Essentially, it becomes a mini project-management tool for the final quality assurance sprint. In a biotech environment, this ensures nothing falls through the cracks in those hectic days before a filing deadline.

8. Final Green Light: Once all critical/high issues are resolved (or consciously waived with justification), the module gives a “Ready to Submit” indication. This doesn’t just mean no errors; it means the submission meets a quality threshold configured by the organization. Some teams might choose to allow minor issues to go (with rationale), but generally the goal is a zero-error package. At this stage, the team can document the findings it resolved or waived and complete its established validation and approval procedures. A clean tool report does not guarantee FDA acceptance, reviewability, or approval.

In our demo, this pre-flight check was the hero because of the immediate impact attendees could see: complex issues that traditionally would be found after sending to FDA (and cause a refusal or delay) were instead caught beforehand. The module turned what could have been a 2-week rework cycle into a 2-hour internal fix. Particularly for emerging biotechs, the value of this is hard to overstate. It levels the playing field – you don’t need a giant regulatory operations team or expensive consultants combing through every detail; the AI assistant has your back, ensuring your submission is as polished as one from a Big Pharma with dedicated QC staff.

One participant in the demo, a regulatory manager at a small biotech, noted that this kind of tool “gives us the confidence that we’re not going to get a nasty surprise from the FDA’s technical screening. We can catch in minutes what might otherwise only show up days later as an RTF letter.” That sentiment captures the essence of the AI pre-flight module’s impact: fewer surprises, fewer delays, and a smoother path forward.

By deploying AI-powered pre-flight checks, emerging biotechs can materially shorten – or outright eliminate – the submission rejection/rework cycle that plagues so many first-time filings. Let’s quantify and summarize the benefits in terms of time saved and process improvements:

• Better pre-submission quality control: Pre-flight checks can help teams find and remediate configured technical issues before submission. FDA’s eCTD criteria explain that High findings prevent processing and require resubmission, while Medium and Low findings have different potential effects on official receipt. A clean pre-flight result does not assure receipt, reviewability, filing, approval, or a particular timeline.

• Faster Review Through Improved Quality: Even beyond outright rejections, a cleaner submission can accelerate the review. Reviewers aren’t stalled by trying to locate information or requesting missing pieces. They can focus immediately on the scientific content. It’s hard to measure, but consider that every time an agency has to ask a clarification question or wait for an additional document, that can introduce a delay of days or weeks (for the sponsor to compile a response, and for the agency to find new time to assess it). If AI suggestions helped the company include those clarifications proactively, you might shave off an entire cycle of Q&A. In regulatory parlance, reducing the rounds of questions can significantly shorten time to approval. While not all queries can be anticipated, even avoiding one round of back-and-forth could cut a few weeks. As the American Pharmaceutical Review article highlighted, feeding prior query knowledge into submissions can lead to applications being “accepted quickly, and first time” ^[22].

• Support for completeness review: Configured checks can help teams identify potentially missing or inconsistent content for qualified review. They do not establish that a dossier is complete or reviewable. For an NDA, FDA has 60 days after initial receipt to decide whether to file it, and an incomplete NDA may receive a refuse-to-file action; the timing and outcome of any subsequent sponsor response are case-specific.

• Efficient Team Utilization: From an operational standpoint, automating these checks means the regulatory team spends far less time in reactive mode. In a traditional scenario, if a submission comes back with a technical issue, the small biotech team has to drop everything to address it, pulling people from other projects. That context switch and scramble is inefficient. With AI doing the heavy QA up front, the team can allocate their time more predictively to get it right the first time. Essentially, you trade a chaotic 2-week fire drill for a smooth 1–2 day polishing phase before submission. That is a huge productivity win and also lowers stress (an often overlooked benefit!).

• Consistent Compliance Culture: Over multiple submissions, AI pre-flight instills a discipline of quality. Teams become aware of what triggers issues and gradually internalize those lessons (especially as the AI reports show them repeatedly). Over time, the number of flagged issues tends to decrease as authors and publishers produce documents correctly from the get-go. This means future submissions require even less rework. For an emerging biotech planning several INDs or eventually an NDA, this consistency can compress timelines across the board.

To put it in real terms: imagine a biotech preparing its first IND. Without AI, they submit and get a technical rejection because some study datasets weren’t in the right format or a crucial hyperlink failed – now the IND is delayed by a month as they scramble to fix it, and their first-in-human trial is postponed accordingly. With robust pre-flight checks, those errors would have been caught in-house. The IND sails through the FDA gate and enters review weeks earlier. That could mean dosing patients earlier and getting clinical answers sooner – a potential life-saving acceleration if the drug works, not to mention maintaining credibility with investors and partners by hitting milestones as planned.

In essence, AI-powered pre-flight checks buy back time that would otherwise be lost to avoidable mistakes. They convert what used to be reactive delay into proactive speed. For an emerging biotech, even a few weeks saved can be the difference in securing the next funding round or beating a competitor to a trial. The reduction in rework also frees the team to focus on science and strategy instead of paperwork fixing.

It’s important to note that regulatory agencies appreciate high-quality submissions as well. A well-prepared dossier that follows all guidelines and is easy to navigate fosters better relations and possibly a smoother review. While agencies won’t formally prioritize an application because it looks nice, the reviewers are human – a submission that respects their time and effort (with neat formatting, working links, clear content) sets a positive tone. There is an indirect but real benefit in how the review proceeds.

By slashing the rework cycles, AI pre-flight tools ultimately shave weeks off the critical path of drug development. And these aren’t risky shortcuts – it’s pure waste reduction (eliminating delays that bring no value). As our deep dive shows, the combination of automated PDF compliance checks, rigorous link validation, and forward-looking GenAI recommendations turns the pre-submission phase into a powerful leverage point for efficiency. Emerging biotechs that embrace these tools can operate with the agility of a startup and the submission precision of a seasoned pharma giant.

Sidebar: Gemini vs. OpenAI Models for Unstructured-Form Extraction

Modern AI models can help extract structured information from unstructured forms and documents. Model availability, pricing, and capabilities change frequently, so teams should consult current vendor documentation and evaluate representative regulated documents in their own controlled workflow.

• Document input:Gemini document processing documents PDF input, including use of the Files API for larger or reusable files. OpenAI file inputs documents PDF input to supported models; the API supplies both extracted text and page images to vision-capable models. These input methods do not establish a universal accuracy, fidelity, or throughput advantage for regulated extraction.

• Structured extraction: Gemini documents structured-output extraction from PDFs. OpenAI Structured Outputs documents schema-constrained JSON output for supported models. In either workflow, validate the output against the source document and the organization’s schema.

• Complex layouts: Gemini documents PDF processing for text, images, diagrams, charts, and tables. OpenAI’s PDF-input documentation describes text and page-image processing for supported vision-capable models. Tables split across pages, multi-column layouts, and handwriting require workload-specific testing.

• Scale, speed, and cost: Capacity, throughput, and cost depend on the selected model, document characteristics, request configuration, rate limits, and current pricing. Gemini’s PDF documentation specifies technical limits, including up to 50 MB or 1,000 pages in the documented workflow. Run controlled tests on representative documents before selecting a provider for batch processing.

Bottom Line: Both APIs document input and output capabilities that can support extraction workflows. Select a model and workflow based on current documentation, data-governance requirements, integration environment, cost, and measured performance on representative regulated documents.

For regulated use, an extracted dataset should be subject to defined validation, traceability, access controls, and qualified human review. An AI tool can support document processing, but it cannot by itself establish completeness, accuracy, regulatory acceptability, or scientific meaning.

In the high-stakes world of biotech regulatory submissions, AI-powered pre-flight checks are emerging as a transformative solution to age-old problems. By automating PDF compliance validation, performing exhaustive broken-link and bookmark audits, and even leveraging generative AI for content suggestions, these tools ensure that submissions are technically sound and substantively robust from the outset. The net effect is a dramatic reduction in the costly rework cycles that have traditionally plagued sponsors – especially smaller companies for whom a month’s delay can make or break the program. An AI-driven pre-flight module acts as a tireless quality guardian, allowing emerging biotechs to punch above their weight in submission excellence.

The case for such technology is compelling: Why risk a several-week delay due to a fixable oversight when an AI can catch it in seconds ^[1]? Why rely solely on human effort for rote checks when an AI can achieve near-perfect thoroughness and free up your team for higher-value work? Early adopters are already reporting faster submissions and fewer agency queries, translating to accelerated timelines. And as regulatory AI tools continue to evolve – with vision models like Google's Gemini 3.1 Pro and OpenAI's GPT-5 pushing the boundaries, and the FDA itself deploying AI assistants like ELSA – we're now firmly in an era where submissions can be not only error-free, but also optimized for first-cycle approval through intelligent insights ^[23].

For emerging biotechs, this technology could be a great equalizer. It mitigates the lack of extensive regulatory operations infrastructure by embedding that expertise into software. In practical terms, it means a lean team can confidently submit a polished, fully compliant application on the first try, focusing their energies on science and strategy rather than firefighting format issues. The weeks saved in avoiding rework are weeks gained for critical development activities or earlier patient access to new therapies.

In conclusion, AI-powered pre-flight checks can help teams identify configured technical issues and organize remediation before submission. They do not guarantee agency acceptance, scientific adequacy, approval timing, or patient outcomes, and should be used alongside formal validation and qualified human review.

Sources: The insights and data points in this article draw from a range of industry guidelines, expert analyses, and technology benchmarks, including FDA eCTD validation criteria ^[30], best-practice guides on submission quality ^[31], McKinsey's 2025 regulatory affairs benchmark ^[26], and recent evaluations of AI document processing like Google's Gemini 3.1 Pro and OpenAI's GPT-5 ai.google.dev. Generative AI use cases in regulatory affairs are based on thought leadership from regulatory technology experts ^[32]. Additional context on FDA's own AI adoption, including ELSA, draws from the FDA's official announcements ^[33] and the AI in regulatory affairs market analysis ^[34]. These references underscore the current state and rapid evolution of AI in transforming regulatory submission workflows.